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Abstract
The management of premature birth still remains unsatisfactory. Since the relative lack of efficiency
and/or safety of current tocolytic agents have been highlighted, it is necessary to develop new
uterorelaxant drugs deprived of important maternal and foetal side effects. Our work reported in
this review focuses on a potential new target for tocolytic drugs, the β3-adrenoceptor (ADRB3).
This third type of ADRB is shown to be present and functional in human myometrium. We
demonstrated that ADRB3 agonists are able to inhibit in-vitro  spontaneous contractions of
myometrial strips, via a cyclic AMP-mediated pathway. Furthermore, we established that ADRB3 is
the predominant subtype over the ADRB2 in human myometrium and that its expression is
increased in near-term myometrium, compared to non-pregnant myometrium. Finally, we reported
that contrary to ADRB2, the human myometrial ADRB3 is resistant to long-term agonist-induced
desensitisation. These compelling data confirm the clinical potential interest of ADRB3 agonists in
the pharmacological management of preterm labour.
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Background and aims
The incidence of premature birth has risen over the past
15 years, mainly because of medically induced births, yet
spontaneous preterm delivery rate continues its steady rise
and remains relatively high in developed countries,
despite preventative measures [1-3]. Approximately 6 to
12% of all pregnancies end up prematurely in Western
countries, and the delivery of infants at preterm periods of
gestation, and the clinical implications thereof, consti-
tutes a major challenge for neonatologists [4]. The mor-
bidity and mortality associated with preterm delivery
outweigh all other clinical problems in obstetric practice
[5-7]. Indeed preterm birth is the most frequent cause of
infant death in the United States, accounting for at least
one third of infant deaths [8]. Several stimulatory and
inhibitory pathways regulate the balance of uterine quies-
cence and contractile activity during pregnancy, but the
specific changes that govern the switch between these
opposing functional states are still poorly understood.
These data explain that a logical research pursuit has been
that of development of pharmacological agents that
inhibit uterine contractions and ideally terminate the
labor process, or delay delivery until gestation is further
advanced.
Unfortunately the efficacy of current pharmacological
treatments for the management of preterm labor is regu-
larly questioned. Among these treatments, β2-adrenocep-
tor (ADRB2) agonists are becoming less used worldwide
as tocolytic agents because of important maternal and
fetal side effects. For these reasons, and the lack of efficacy,
much research in the last decade has focused on the devel-
opment of novel agents, such as calcium channel blockers
and oxytocin antagonists [9-12]. In countries outside of
the United States, these agents have now largely displaced
the use of ADRB2 agonists as tocolytic compounds, but
the data to support their use, in terms of clinical efficacy,
are lacking.
Although ADRB were originally sub-classified into ADRB1
and ADRB2 [13], another subtype, the ADRB3-subtype,
has been since reported [14]. The ADRB3 shares 40 to
50% amino acid sequence identity with ADRB1 and
ADRB2. It has been shown to mediate lipolysis in white
adipose tissue and thermogenesis in brown adipose tissue
[15,16], and to inhibit the contractile activity of ileum and
colon [17].
In the heart, ADRB pathways are the primary means of
increasing cardiac performance in response to acute or
chronic stress. The presence and function of the ADRB3 in
the cardiovascular system is a conflicting debate. Indeed it
has recently been suggested that ADRB3 are expressed in
the endothelium of human coronary resistance arteries, or
internal mammary arteries, and mediate adrenergic
vasodilatation [18,19].
Myometrium has always been described as expressing pre-
dominantly? ADRB2 [20-23] and the presence of ADRB3
had never been studied prior to our investigations pre-
sented here.
These works aimed to assess the presence and function of
ADRB3 in human myometrium and to assess the influ-
ence of pregnancy in its expression as well as its ability to
resist to agonist-induced desensitization.
Results
The ADRB3 is present and functional in human near term 
myometrium
Our first approach consisted of investigating the presence
of the ADRB3 in human near-term myometrium [24]. In-
vitro functional studies were performed to compare the
effects of ADRB2 and ADRB3 agonists on spontaneous
contractions. SR 59119A, a selective ADRB3 agonist, pro-
duced a concentration-dependent inhibition of spontane-
ous contractions (Figure 1), with a maximal effect of 52 ±
7% compared with 27 ± 6% for salbutamol (Figure 2).
The pharmacological evidence of the ADRB3-mediated
nature of this effect was supported by the use of ADRB
antagonists. Indeed, propranolol, at a concentration that
blocks ADRB1&2 but not ADRB3 [25], and ICI 118551,
an ADRB2 antagonist, did not affect the SR 59119A-
induced relaxation whereas the ADRB3 antagonist [26],
SR 59230A, significantly reduced the maximal effect of SR
59119A. To assess the nature of the second messenger
involved in the uterorelaxant effect of SR 59119A, we
measured the production of cAMP and cGMP after a stim-
ulation of myometrial strips with SR 59119A or salbuta-
mol. Both SR 59119A and salbutamol induced a
significant increase in cAMP levels, but not of cGMP. The
production of cAMP was antagonized by SR 59230A but
not by propranolol for SR 59119A, providing confirma-
tion of the ADRB3-mediated nature of this stimulation.
Using an RT-PCR approach we found that mRNA expres-
sion was detected, as an expected 650 bp fragment, in
human myometrium (Figure 3). Hybridization to human
ADRB3  cDNA confirmed the identity of the amplified
products.
A somewhat similar pharmacological study was published
by Dennedy et al. in 2001 [27], on this occasion compar-
ing the functional effects of the ADRB3 agonist BRL
37344, with those of the commonly used ADRB2 agonist,
ritodrine, on human pregnant myometrial spontaneous
or oxytocin-induced contractility. Mean maximal inhibi-
tion of contractility values of approximately 60% were
reported for both compounds, at tissue bath concentra-
tions in the 10-5 molar range. There was no differenceBMC Pregnancy and Childbirth 2007, 7(Suppl 1):S14 http://www.biomedcentral.com/1471-2393/7/S1/S14
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between calculated pD2 values, or mean maximal inhibi-
tion achieved, for both compounds (Table 1).
As a logical follow on to the above findings, Dennedy et
al. [28] further evaluated the selectivity of ADRB3 agonists
in human myometrium. Using bupranolol (an ADRB1,
ADRB2, and ADRB3 antagonist), propranolol (an ADRB1
and ADRB2 antagonist) and butoxamine (an ADRB2
antagonist), it was demonstrated that the myorelaxant
effect of BRL 37344 was mediated via the ADRB3,
although ritodrine may exert its effects via ADRB1, ADRB2
and ADRB3.
The ADRB3 is predominant over the ADRB2 and its 
expression is increased during pregnancy
Whereas the existence of the third ADRB subtype had not
been shown yet formally, we previously described that
ADRB2 were predominant (65%) over ADRB1 in the
human myometrium and that the number of ADRB was
diminished at the end of pregnancy [20]. In the light of
our new results, we wanted to assess the influence of preg-
nancy on the function and the expression of the myome-
trial ADRB3-subtype [29]. To this end, we performed in-
vitro studies in human non-pregnant and near-term myo-
metrium and found that SR 59119A inhibited spontane-
ous contractions of pregnant myometrial strips in a
greater extent than that of non-pregnant myometrial strips
(Emax = 61 ± 5% vs. 44 ± 5% for pregnant and non-preg-
nant myometrium respectively). On the contrary, salbuta-
mol was less efficient in pregnant than in non-pregnant
myometrial strips (Emax = 29 ± 4% vs. 54 ± 8%). Binding
competition studies, transcripts and protein analysis were
then performed to determine whether any changes in the
number of ADRB2 and ADRB3 binding sites and in the
transcript and protein expression might explain the
observed change in the contractile response between non-
pregnant and pregnant myometrium to ADRB2 and
ADRB3 agonists. Although two populations of binding
sites corresponding to ADRB2 and ADRB3 were identified
in both non-pregnant and pregnant myometrium, we
found a clear predominance of the ADRB3 subtype, a
result that contrasts with conventional belief. Moreover,
Representative recording of the effect of SR 59119A on spontaneous contractions of human non-pregnant (upper trace) and  near-term (lower trace) myometrial strips Figure 1
Representative recording of the effect of SR 59119A on spontaneous contractions of human non-pregnant (upper trace) and 
near-term (lower trace) myometrial strips.
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ADRB3 binding sites were 2-fold more numerous at the
end of pregnancy, whereas, according to the work of Gsell
et al. [30], we found no modification in the number of
ADRB2 binding sites in non-pregnant compared to preg-
nant human myometrium.
Densitometric analysis of the RT-PCR experiments indi-
cated a slight decrease in the signal for ADRB2 mRNA (-
27.4%) in near-term myometrium comparatively to non-
pregnant tissue whereas the signal for ADRB3 mRNA was
increased in pregnant myometrium (+66.3%).
In agreement with Chanrachakul et al. [31], densitometric
immunoblot analysis indicated no change in the intensity
of the signal for the ADRB2 in the myometrium of near-
term compared to non-pregnant women. At the opposite,
an increase (+40%) in the intensity of the signal for the
ADRB3 protein was observed in pregnant compared with
non-pregnant myometrium (Figure 4).
Contrary to the ADRB2, the ADRB3 is resistant to agonist-
induced desensitization
Besides their maternal and fetal side effects, ADRB2 ago-
nists display a lack of efficacy in late pregnancy or after a
chronic exposure [32,33]. This loss of efficacy, also called
desensitization, may be partly explained by a decreased
number of ADRB2 at the end of pregnancy, as well as by
an impairment of the coupling between the receptor and
its effector, the adenylyl cyclase. ADRB3 was suggested to
be less prone than ADRB2 to desensitisation [34]. This
Table 1: Emax, pD2 and intrinsic activity (IA) for the different ADRB2 or ADRB3 agonists presented in this paper
Compounds Emax pD2 IA
Isoprenaline 58% ± 9% 7.32 ± 0.62 100% (ref)
Salbutamol 27% ± 6% 6.0 ± 0.48 48% ± 7%
Ritodrine 62% ± 5% 7.26 ± 0.48 107% ± 6%
BRL 37344 60% ± 4% 7.64 ± 0.53 103% ± 4%
SR59119 52% ± 7% 5.65 ± 0.14 90% ± 7%
Emax is expressed as a percentage of inhibition compared with initial amplitude of the contractions. The intrinsic activity (%IA) relative to the 
maximal effect of (-)-isoproterenol indicate the inhibition of the initial amplitude of spontaneous contractions.
Concentration-response curve for SR59119 and Salbutamol  (ADRB3 and ADRB2 agonists respectively) in human near  term myometrium Figure 2
Concentration-response curve for SR59119 and Salbutamol 
(ADRB3 and ADRB2 agonists respectively) in human near 
term myometrium.
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Representative RT-PCR analysis of the mRNA steady-state  levels for ADRB2 and ADRB3 in human pregnant myo- metrium Figure 3
Representative RT-PCR analysis of the mRNA 
steady-state levels for ADRB2 and ADRB3 in human 
pregnant myometrium. The 123-bp DNA ladder (λ 123) 
was used to estimate the size of the PCR products, and beta2 
microglobulin expression was used as a standard reference.
ADRB2 ADRB3 O123
E2-microglobulinBMC Pregnancy and Childbirth 2007, 7(Suppl 1):S14 http://www.biomedcentral.com/1471-2393/7/S1/S14
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particularity may be due to a lack of recognition sites in
ADRB3 for the cyclic AMP-dependent protein kinase and
for the G-protein coupled receptor kinase implicated in
the desensitization process of ADRB2. In order to confirm
this hypothesis in human near-term myometrium, we
investigated the effects of a long-term (15 h) exposure of
myometrial strips to SR 59119A or to salbutamol on the
inhibition of spontaneous contractile activity and on the
cAMP production induced by these agonists [35]. In our
experimental conditions, we demonstrated that ADRB2
undergoes functional desensitization after long-term
exposure to salbutamol, since salbutamol concentration-
response curve (CRC) was shifted by a 15 h salbutamol
pre-incubation with a significant difference in -logEC20
ADRB2 and ADRB3 immunoreactive proteins expression in myometrium of non-pregnant and pregnant women Figure 4
ADRB2 and ADRB3 immunoreactive proteins expression in myometrium of non-pregnant and pregnant 
women. (A) Representative western blot analysis of ADRB2- and ADRB3 expression in plasma membranes from myo-
metrium of non-pregnant and pregnant women. Expected sizes are 67 kDa for ADRB2 and 68 kDa for ADRB3. These experi-
ments were performed on myometrium from five non-pregnant and five pregnant women. Homogenate of Chinese Hamster 
Ovary cells transfected with the human ADRB3 (ADRB3-CHO) was used as positive control. (B) Analysis of the expression of 
ADRB2 and ADRB3 immunoreactive proteins in myometrium of non-pregnant and pregnant women. A.D.U. represents the 
intensity of the bands evaluated by densitometry. Each bar represents the mean ± s.e.m. from five different non-pregnant and 
five different pregnant women. Figure reproduced from the paper by Rouget et al. [29].
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values (6.31 ± 0.13 vs. 5.58 ± 0.24, for control and 15 h
salbutamol pre-treatment respectively, P < 0.05). Addi-
tionally a 15 h exposure of myometrial strips to salbuta-
mol significantly reduced the salbutamol-induced (0.60 ±
0.26 vs. 1.54 ± 0.24 pmol.mg-1 protein, P < 0.05) cAMP
production. In contrast, a sustained stimulation by SR
59119A did not modify its subsequent functional effects.
A 15 h salbutamol exposure of myometrial strips signifi-
cantly reduced the ADRB2 but not the ADRB3 binding
sites density whereas no decrease in the number of ADRB2
and ADRB3 binding sites was observed after a 15 h SR
59119A treatment. RT-PCR experiments and PDE4 activ-
ity measurement were performed in order to assess some
of the mechanisms that could be involved in desensitiza-
tion process and we found that neither ADRB2  and
ADRB3 mRNA expression levels nor PDE4 activity were
affected by salbutamol or SR 59119A treatments.
Discussion and conclusion
Taken altogether our results indicate that ADRB3 is: i)
present and functional in human near term myometrium,
ii) predominant over ADRB2 in human myometrium and
over-expressed in pregnancy, and iii) resistant to the long-
term agonist-induced desensitization in human myo-
metrium at the end of pregnancy.
The presence of ADRB3 in human myometrium was con-
firmed in a work by Hakak et al. [36] who compared the
ADRB3 expression in Human and mouse. In this paper
the two key messages were as follows: (i) ADRB3 expres-
sion differs strongly between Human and Mouse myo-
metrium and (ii) human ADRB3 is highly expressed in
placenta, ovaries and myometrium (the relative level of
expression being as follow: placenta = bladder > aorta >
ovary > myometrium)
To conclude, our work strongly suggests the ADRB3 as a
potential target for tocolytic agents. The greater relaxant
effectiveness of ADRB3 agonists compared to ADRB2
mimetics, as well as the resistance of ADRB3 to sustained
agonist-induced desensitization strengthens this concept.
We previously mentioned maternal and fetal cardiovascu-
lar side effects as one of the major limitations for ADRB2
agonists' use in clinical practice. There is strong evidence
to suggest a favorable safety profile, probably better than
that of ADRB2 agonists and calcium channels antagonists.
Indeed clinical trials, that were designed to assess the
effect of ADRB3 agonists on human metabolism, did not
reveal any significant change in heart rate, blood pressure,
plasma glucose, insulin or potassium levels [37].
Although the therapeutic efficiency of the ADRB3 agonists
remains to be established, we believe that ADRB3 agonists
may have considerable future pharmaceutical implica-
tions in the clinical management of preterm labor.
List of abbreviations
ADRB, beta-adrenergic receptor; CAMP, cyclic adenosine
monophosphate; CGMP, cyclic guanosine monophos-
phate; CRC, concentration response curve; Emax, maxi-
mal efficacy; PDE, phosphodiesterases; RT-PCR, real time
polymerase chain reaction.
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